DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
-
Published:2023-11
Issue:
Volume:45
Page:100937
-
ISSN:1476-5586
-
Container-title:Neoplasia
-
language:en
-
Short-container-title:Neoplasia
Author:
Bon Giulia,
Krasniqi Eriseld,
Porru ManuelaORCID,
D'Ambrosio Lorenzo,
Scalera StefanoORCID,
Maugeri-Saccà Marcello,
Di Lisa Francesca Sofia,
Filomeno Lorena,
Arcuri Teresa,
Botticelli Andrea,
Santini Daniele,
Fabbri Maria Agnese,
D'Auria Giuliana,
Pulito ClaudioORCID,
Blandino Giovanni,
Marchiò Caterina,
Barba Maddalena,
Ciliberto Gennaro,
Vici PatriziaORCID,
Pizzuti Laura
Funder
Ministero della Salute
Reference10 articles.
1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a multicenter, double-blind, placebo-controlled, phase 3 study;Swain;Lancet Oncol.,2013
2. How we treat patients with metastatic HER2-positive breast cancer;Nader-Marta;ESMO Open,2022
3. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study;Bon;J. Clin. Exp. Cancer Res.,2020
4. Stemming the tide of drug resistance in cancer;Mullard;Nat. Rev. Drug Discov.,2020
5. Combating subclonal evolution of resistant cancer phenotypes;Brady;Nat. Commun.,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献